Figma Shares Indicated To Open $105/$110
In a recent transaction, Mark Coleman, a director at Axsome Therapeutics, Inc. (NASDAQ:AXSM), sold 3,000 shares of the company’s common stock. The biopharmaceutical company, currently valued at $5.36 billion, has demonstrated impressive growth with revenue increasing by 72% over the last twelve months. The shares were sold on May 20, 2025, at a weighted average price of $107.491, resulting in a total transaction value of approximately $322,473. Following this sale, Coleman directly owns 54,137 shares of Axsome Therapeutics. Additionally, he holds 403,856 shares indirectly through an entity where he has voting and dispositive power. According to InvestingPro, the company maintains impressive gross profit margins of over 91%, though analysts note it’s currently trading above its Fair Value. InvestingPro subscribers have access to 6 additional key insights about AXSM, along with comprehensive financial analysis in the Pro Research Report.
In other recent news, Axsome Therapeutics reported its first-quarter 2025 financial results, highlighting a significant year-over-year revenue increase of 62%, totaling $121.46 million. Despite this growth, the revenue fell slightly short of the forecasted $121.58 million, while the company exceeded earnings per share expectations with a loss of $1.22 per share, better than the anticipated loss of $1.30. Axsome also secured a $570 million credit facility from Blackstone (NYSE:BX), which includes a $500 million term loan and a $70 million revolving credit facility, aimed at strengthening its financial position. This move allows Axsome to retire its previous loan with Hercules Capital (NYSE:HTGC), potentially reducing interest expenses.
Analysts from H.C. Wainwright lowered Axsome’s stock price target to $180 from $200, maintaining a Buy rating, citing higher-than-expected operating expenses and a revised revenue forecast. Meanwhile, BofA Securities increased the stock price target slightly to $176, also maintaining a Buy rating, citing strong prescription growth for its product Auvelity-MDD. The company is preparing to launch SYMBRAVO for migraines, with positive results from its Phase 3 trial noted. With $300.9 million in cash at the end of the quarter, Axsome anticipates reaching cash flow positivity early next year, supported by its current capital.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.